Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT	OF CHANGE	S IN BENEFI	CIAL OW	/NERSHIP

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol OBALON THERAPEUTICS INC [OBLN]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
MOATAZEDI DAVID					٦	D111			IUII LO		<u> </u>	L ODE	`	X	Directo	r		10% Ow	ner
	ALON THE	RAPEUTICS, I				3. Date of Earliest Transaction (Month/Day/Year) 03/13/2017									Officer below)	(give title		Other (s below)	pecify
5421 AVENIDA ENCINAS, SUITE F				4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable					
(Street)	BAD C	A	92008											Line) X	Form filed by One Repo Form filed by More than Person			•	
(City)	(S	tate)	(Zip)																
		Tab	le I - Nor	ı-Deri	vativ	e Se	curities	Ac	quired, D	)isp	osed o	of, or Be	nefici	ially	Owned				
1. Title of Security (Instr. 3)  2. Transa Date (Month/D				Execution Date		Code (Instr. 5)				and Securitie Benefici Owned F		s illy ollowing	Form	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership				
								Code	V	Amount	(A) or Pric		e	Reported Transact (Instr. 3 a	tion(s)			Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	ate Execution D	Date, Transac Code (II				ve es d ed nstr.	6. Date Exercis Expiration Date (Month/Day/Yea		of Securities		ties ng e Securi	Derivative Security		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amou or Numb of Share	er					
Stock Option (Right to Buy)	\$9.55	03/13/2017			A		59,988		(1)	0	3/12/2027	Common Stock	59,98	38	\$0.00	59,988	3	D	

## **Explanation of Responses:**

1. The vesting commencement date ("Vesting Commencement Date") of the option is March 13, 2017. The option vests (i) with respect to one-thirty sixth (1/36) of the shares underlying the option on the first month anniversary of the Vesting Commencement Date and (ii) with respect to 1/36th of the shares underlying the option, on each monthly anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person's continued service with the Issuer through the applicable vesting dates.

## Remarks:

/s/ David Moatazedi

03/15/2017

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.